Communication between cells is particularly important during tumour progression. Communication can take place through direct cell-cell interactions, but also through extracellular secretion of mediators acting at a distance. These mediators can be either soluble molecules or more complex structures called membrane vesicles, enclosing soluble factors within a lipid bilayer. A variety of extracellular membrane vesicles have been described, for instance microvesicles, ectosomes and a subtype called exosomes. The role of exosomes in tumour progression has been studied extensively in the last 10 years. In the present mini-review, we discuss our recent results, first showing the heterogeneity of the vesicles called exosomes and the probable existence of subpopulations of these exosomes, and secondly demonstrating that in vivo secretion of exosomes by some tumours can promote tumour progression, but that such a function cannot be generalized to all tumours and all exosomes.
Introduction
proposed to differ from the other membrane vesicles by their size, density and specific composition of lipids, proteins and nucleic acids, which reflects their endocytic origin. Exosomes have been defined previously as measuring from 50 to 100 nm in diameter, sedimenting at 100 000 g, floating on a sucrose gradient at a density ranging from 1.13 to 1.19 g/ml and appearing cup-shaped when observed by electron microscopy [9] . Some proteins are highly enriched in exosomes in comparison with cell lysates and are commonly used as markers to identify exosomes: the ESCRT (endosomal sorting complex required for transport) proteins Alix [ALG-2 (apoptosis-linked gene 2)-interacting protein X] and Tsg101 (tumour-suppressor gene 101), the tetraspanins CD63, CD9 and CD81, some Hsps (heat-shock proteins), e.g. Hsp90, the constitutive Hsc70 (heat-shock cognate 70) or the heatinducible Hsp70, MHC class II molecules and Mfge8 (milk fat globule-epidermal growth factor-Factor VIII protein).
The combination of these different characteristics constituted, until recently, the most precise definition of exosomes, allowing us to distinguish them from other vesicles produced by the cells. In a recent study, however, we showed that some of these classical exosome markers are not specific to exosomes, compared with other vesicles [10] . CD9 and Mfge8 were both highly enriched in mouse tumour-derived exosomes (obtained by ultracentrifugation at 100 000 g), but also in microvesicles (ultracentrifugation at 10 000 g), whereas CD63, Alix, Tsg101 and Hsc70 were present at high levels only in exosomes [10] (Figure 1 ). These latter proteins thus seem to be more specific exosome markers than CD9 and Mfge8. It would thus now be important to compare the enrichment in the different types of extracellular vesicles of all other proteins used by different groups to characterize exosomes.
Figure 1 Diversity of extracellular vesicles
Proteins classically used, by us and others, as markers of exosomes are in fact also abundant on larger vesicles, precipitated by ultracentrifugation at 10 000 g: CD9 and Mfge8. Rab27a inhibition induced a decrease in secretion of exosomes bearing the endosomal markers CD63, Tsg101, Alix, Hsc70 (and CD9 and Mfge8), but not of other vesicles co-purified by ultracentrifugation at 100 000 g and bearing mainly CD9 and Mfge8, nor of the larger vesicles. The origin of the vesicles co-purified with Rab27a-dependent endosome-derived exosomes is not yet established. Summary of results from [10] .
Heterogeneity of exosomes?
Some degree of heterogeneity of the exosomes obtained by ultracentrifugation from a given type of cell could be observed on electron microscopy images published by several groups, of exosomes derived from various cells, such as antigen-presenting cells [11] [12] [13] or tumour cells [14, 15] . It was also noted that the different exosome markers did not behave similarly on a sucrose gradient, meaning that the exosome preparations were composed of various vesicles slightly different in their density and in their enrichment for the distinct proteic markers. Indeed, although exosome markers float in sucrose fractions ranging from 1.10 to 1.19 g/ml, the fractions within this range are not identical. A study performed on B-cell-derived exosomes showed that MHC class II molecules were highly enriched in the 1.13 g/ml density fraction, whereas CD82 was in the 1.12-1.13 g/ml fractions and CD81 in the 1.13-1.14 g/ml fractions [16] . A more recent study on exosomes purified from seminal liquid showed that the markers CD9 and PSCA (prostate stem cell antigen) were not equally present in the different density fractions, after 16 h of flotation on the sucrose gradient, with a high enrichment of CD9 in fractions of densities above 1.20 g/ml [17] . But the authors also showed that after 62 h of flotation, these two markers presented similar profiles on the sucrose gradient, i.e. densities of 1.12-1.19 g/ml, meaning that the densest fractions contained vesicles that had not reached their equilibrium density after 16 h of flotation. We recently obtained consistent results on tumour-derived mouse exosomes [10] : we showed that the tetraspanins CD9 and CD63 were abundant in the highest density fractions of the sucrose gradient, whereas Mfge8 was absent after 16 h of flotation, but all were recovered in the 1.13-1.19 g/ml range after 62 h of flotation.
In this same study, we used inhibition of Rab27a expression to block exosome secretion. Rab proteins are small GTPases involved in many steps of the intracellular trafficking (coating, budding of the vesicles from the donor compartment, uncoating, transport along the cytoskeleton, tethering and fusion with the acceptor compartment) and are present in almost every internal membrane compartment. A previous study in the laboratory aimed to screen the Rab protein family to assess their role in exosome secretion in HeLa human tumour cells. Rab27a and Rab27b were found to be necessary for the secretion of exosomes, but not for the secretion of a soluble protein (ovalbumin) through the classical secretion pathway [18] . More recently, using murine mammary tumour cells, we found that only Rab27a, and not Rab27b, was involved in the secretion of exosomes in these cells [19] . In other cell types, different groups have identified other Rabs involved in the exosome secretion pathway: Rab11 participates to the Ca 2 + -regulated secretion of exosomes by a erythroleukaemia tumour cell line [20] , and Rab35 was required for the secretion of PLP (proteolipoprotein)-enriched exosomes by oligodendrocytes [21] , although neither of these Rabs was involved in exosome secretion by the HeLa cells used in our screen [18] . Thus, today, there is no consensus on the intracellular machinery involved in exosome secretion, since it seems to be dependent on the cell type, and also on which exosome-addressed molecule is considered. Indeed, by analysing simultaneously secretion of six different exosomal proteins by the mouse cells after Rab27a invalidation [10] , we could show different behaviours of these markers. The 'endosome-associated exosome markers' (CD63, Alix, Tsg101 and Hsc70) were, as expected, almost undetectable in the 100 000 g pellet obtained from Rab27a-impaired cells, whereas CD9 and Mfge8 were, surprisingly, not decreased compared with the pellet obtained from control cells. Thus two groups of vesicles can be distinguished according to their secretion pathway: those bearing CD63, Alix, Tsg101 and Hsc70 (and also CD9 and Mfge8) produced in a Rab27a-dependant manner as shown previously [18] , and those bearing mainly CD9 and Mfge8 produced independently of Rab27a (Figure 1 ). Apart from their composition and their biogenesis, these vesicles also differed in their sizes and densities. We do not know how the CD9-and Mfge8-enriched vesicles are produced by the cells, namely whether they bud from the plasma membrane or are coming from other intracellular compartments associated with a different molecular machinery. Previously, it had been shown that epithelial cells produce, at their apical pole, exosomes that were different in size and composition from those secreted at their basal pole [22] . This work indicates the possibility that at least two different machineries of exosome secretion may coexist in the same cell [22] . The community of researchers working on exosomes will have to characterize and define the different populations of vesicles that are present in the exosome pellet. To achieve this aim, our knowledge of exosome biogenesis and of their secretion pathway(s) will need to be improved. More discriminant purification techniques will also have to be set up in order to obtain more homogeneous vesicle preparations, and to separate the different populations of exosomes, or the exosomes from the other vesicles.
Exosome functions in vivo: focus on tumour-derived exosomes
After their production, exosomes can interact with potential target cells in many different ways as detailed in a previous review [8] . Exosomes coming from the different cell types could thus be the conveyors of messages from one cell to another, but their true physiological functions are still unclear.
In particular, the function of exosome secretion in the context of tumour development is an important question for future development of new therapies. Many groups are thus working on this issue, and, depending on their composition in proteins and nucleic acids, tumour exosomes have been proposed to modulate angiogenesis, promote metastasis, transfer oncogenic proteins and modulate the immune response in either a pro-or an anti-tumoral manner. We will not detail these studies in the present paper, since there have been some very recent reviews of this work [23] [24] [25] . We stress, however, that it is still not clear from most of these studies whether the functions described are specific to endosome-derived exosomes, or are shared between some or even all subtypes of secreted vesicles, since the vesicle preparations used contain different subtypes of vesicles, even when the most accurate protocols for purification are used. In addition, none of these studies compared the functions of the different vesicle subtypes side-by-side, and, in some cases, the authors decided to use bulk preparations of all large and small vesicles secreted by cultured cells. Finally, all of these studies have been performed using vesicles or exosomes purified and concentrated in vitro, and, even if the effects of these vesicles are analysed in vivo after injection in animal models, none assesses the functions of 'untouched' exosomes produced in vivo.
To overcome this artefactual situation, we have decided to study the role of exosome secretion in a more physiological context, by manipulating tumour cells in vitro, to affect in a stable manner their exosome secretion, and then analyse in vivo the behaviour of these modified tumours, in terms of tumour growth and interaction with the immune system. Our first approach was to create a tumour cell line secreting exosomes bearing a model antigen, OVA (ovalbumin) [26] . This was performed by inducing the expression of a fusion protein composed of the OVA antigen and of the C1C2 part of Mfge8 in MCA tumour cells. The antigen secreted by these cells thus localizes on extracellular vesicles owing to the interaction between the C1C2 domain and the phosphatidylserine exposed on the vesicles. These tumours grow slower in immunocompetent hosts than the corresponding tumours producing a soluble non-membranebound form of the antigen, and are completely rejected in the presence of OVA-specific T-lymphocytes. We thus concluded that in vivo secretion of exosomes containing an antigen by tumours could promote induction of antitumour immune responses in vivo, eventually preventing tumour progression. Our more recent evidence that Mfge8, even though it is highly enriched on exosomes, is also very abundant on other types of extracellular vesicles [10] suggests that other extracellular vesicles would, in vivo, also bear this antigen. Thus the increased efficiency of immune responses induced by the modified antigen in vivo could not be specifically attributed to its secretion on exosomes, but more generally on extracellular vesicles. Other groups have since used the C1C2-based modification of antigens [27, 28] , and, in these studies too, the specificity of targeting to exosomes should be re-evaluated. In conclusion, exosomes and other secreted vesicles may still differently participate in the immune response, and the respective amount of each type of vesicles secreted in vivo could determine the final proor anti-tumoral outcome.
Our second approach was thus to affect specifically exosome secretion in vivo, and to compare tumour development and the tumour-induced immune response of murine mammary tumours in which the secretion of exosomes was inhibited or not. A 50 % decrease in exosome secretion was obtained by the abolition of Rab27a expression in two mouse mammary carcinoma cells that were then injected subcutaneously in immunocompetent mice [19] . In the 4T1 model, whereas control tumours grew progressively and formed metastases, those that were inhibited for Rab27a expression almost did not develop. We could demonstrate In the 4T1 mouse mammary carcinoma cell line, inhibition of Rab27a expression led to a decrease in exosome secretion, but also of non-exosome-associated MMP9, known to promote metastasis formation by 4T1. Exosomes, combined with other soluble factors whose secretion was not impaired upon Rab27a inhibition, promote differentiation and recruitment to the tumour of neutrophils, necessary for 4T1 progression. Note that this mechanism does not apply to the other carcinoma cell line, TS/A, which progresses independently of neutrophils, and secretes different exosomes and a different range of soluble factors. Summary of results from [19] .
that, in this model, a combination of tumour exosomes together with some tumour-derived soluble factors promoted the differentiation, recruitment into the tumour and/or activation of pro-tumoral neutrophils shown to be necessary for 4T1 tumour growth [19] (Figure 2) . But, in a second model, TS/A, Rab27a inhibition did not prevent tumour growth, and we did not observe a positive role of TS/A exosomes in tumour progression. We could show that TS/A secretes a different array of soluble factors, but also functionally different exosomes, and finally that it does not rely on neutrophils for its progression, indicating that exosome functions may be tumour-specific.
We also want to stress that inhibiting Rab27a expression was also affecting the secretion of a subset of soluble factors by the mouse tumour cell lines. In particular, Rab27a-impaired cells no longer secreted MMP9 (matrix metalloproteinase 9), which we showed was not associated with exosomes [19] (Figure 2) , and which is required for efficient metastasis of 4T1 [29] . It is thus important to note that Rab27a is not a tool to modulate specifically the secretion of exosomes, and complementary experiments must be performed, as we did, to unravel the relative contributions of exosomes and soluble factors whose secretion is dependent on Rab27a.
Conclusions
Exosomes are one particular category of vesicles among all the extracellular membrane vesicles produced by cells. It will be important to define very precisely which vesicles can be called exosomes or not, i.e. which criteria must be present to classify a vesicle as an exosome. Methods of purification and characterization will also need to be improved in order to obtain pure preparations of exosomes, and to easily identify them. We found that the vesicles obtained with the classical purification method of differential ultracentrifugation are heterogeneous in their size, density, composition and biogenesis. We are now trying to understand whether all these vesicles are a different kind of exosomes coming from different types of intracellular multivesicular compartments, or whether only some can be considered to be exosomes. Many functions have been attributed to exosomes, but, most of the time, exosomes were not studied under physiological conditions. By contrast, our most recent results provide the first demonstration that tumour exosomes can play a pathophysiological role in vivo, but they also highlight the specificity of each tumour microenvironment, and the fact that tumour-promoting functions of tumourderived exosomes is not a general rule. Finally, for clinical applications, exosomes have the potential to be used in anti-tumour treatments: a clinical trial in non-small-cell lung cancer using exosomes from a patient's dendritic cells is currently running in France [30] , and knowing better which exosomes display the most efficient antigen-presenting activity will help to improve their utilization. Another clinical trial using tumour exosomes as stimulators of the anti-tumour immune response has been performed in China [31] , but we could also think of the converse strategy: to inhibit their secretion by the tumour, or their interaction with their target cells. Refining our knowledge of tumour-derived exosomes' nature, composition and functions will help us to improve their utilization as diagnostic markers and in anti-tumour therapies.
